Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL

Science Translational Medicine

Volumn 8, Issue 339, 2016, Pages

  McComb, Scott ^a   Aguadé Gorgorió, Júlia ^a   Harder, Lena ^a   Marovca, Blerim ^a   Cario, Gunnar ^b   Eckert, Cornelia ^c   Schrappe, Martin ^b   Stanulla, Martin ^d   Von Stackelberg, Arend ^c   Bourquin, Jean Pierre ^a   Bornhauser, Beat C ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BIRINAPANT; BORTEZOMIB; CASPASE 8; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MERCAPTOPURINE; MESSENGER RNA; OBATOCLAX; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 1; RECEPTOR INTERACTING PROTEIN KINASE 3; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TIOGUANINE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VENETOCLAX; VINCRISTINE; AGFG1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DIABLO PROTEIN, HUMAN; DIPEPTIDE; INDOLE DERIVATIVE; MITOCHONDRIAL PROTEIN; NUCLEOPORIN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN; RNA BINDING PROTEIN; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DRUG RESPONSE; EX VIVO STUDY; FEMALE; GENE DISRUPTION; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA RELAPSE; MALE; MOUSE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; NECROSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DIPEPTIDES; DRUG SYNERGISM; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MITOCHONDRIAL PROTEINS; NECROSIS; NUCLEAR PORE COMPLEX PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RNA-BINDING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84969626016     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad2986     Document Type: Article

References (52)

1. F. Locatelli, M. Schrappe, M. E. Bernardo, S. Rutella, How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120, 2807-2816 (2012).
2. E. Curran, W. Stock, How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood 125, 3702-3710 (2015).
3. C. G. Mullighan, Genomic characterization of childhood acute lymphoblastic leukemia. Semin. Hematol. 50, 314-324 (2013).
4. S. Fulda, Tumor resistance to apoptosis. Int. J. Cancer 124, 511-515 (2009).
5. P. E. Czabotar, G. Lessene, A. Strasser, J. M. Adams, Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49-63 (2014).
6. S. Fulda, D. Vucic, Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11, 109-124 (2012).
7. E. C. LaCasse, D. J. Mahoney, H. H. Cheung, S. Plenchette, S. Baird, R. G. Korneluk, IAPtargeted therapies for cancer. Oncogene 27, 6252-6275 (2008).
8. C. Holohan, S. Van Schaeybroeck, D. B. Longley, P. G. Johnston, Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
9. Y. Suzuki, Y. Nakabayashi, K. Nakata, J. C. Reed, R. Takahashi, X-linked Inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J. Biol. Chem. 276, 27058-27063 (2001).
10. M. J. M. Bertrand, S. Milutinovic, K. M. Dickson, W. C. Ho, A. Boudreault, J. Durkin, J. W. Gillard, J. B. Jaquith, S. J. Morris, P. A. Barker, cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689-700 (2008).
11. J. Silke, J. A. Rickard, M. Gerlic, The diverse role of RIP kinases in necroptosis and inflammation. Nat. Immunol. 16, 689-697 (2015).
12. D. J. Mahoney, H. H. Cheung, R. L. Mrad, S. Plenchette, C. Simard, E. Enwere, V. Arora, T. W. Mak, E. C. Lacasse, J. Waring, R. G. Korneluk, Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation. Proc. Natl. Acad. Sci. U.S.A. 105, 11778-11783 (2008).
13. R. Weinlich, D. R. Green, The two faces of receptor interacting protein kinase-1. Mol. Cell 56, 469-480 (2014).
14. C. P. Dillon, R. Weinlich, D. A. Rodriguez, J. G. Cripps, G. Quarato, P. Gurung, K. C. Verbist, T. L. Brewer, F. Llambi, Y.-N. Gong, L. J. Janke, M. A. Kelliher, T.-D. Kanneganti, D. R. Green, RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 157, 1189-1202 (2014).
15. W. J. Kaiser, L. P. Daley-Bauer, R. J. Thapa, P. Mandal, S. B. Berger, C. Huang, A. Sundararajan, H. Guo, L. Roback, S. H. Speck, J. Bertin, P. J. Gough, S. Balachandran, E. S. Mocarski, RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc. Natl. Acad. Sci. U.S.A. 111, 7753-7758 (2014).
16. D. Ofengeim, J. Yuan, Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat. Rev. Mol. Cell Biol. 14, 727-736 (2013).
17. D. E. Christofferson, Y. Li, J. Yuan, Control of life-or-death decisions by RIP1 kinase. Annu. Rev. Physiol. 76, 129-150 (2014).
18. M. Pasparakis, P. Vandenabeele, Necroptosis and its role in inflammation. Nature 517, 311-320 (2015).
19. L. Bai, D. C. Smith, S. Wang, Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol. Ther. 144, 82-95 (2014).
20. S. Fulda, Promises and challenges of Smac mimetics as cancer therapeutics. Clin. Cancer Res. 21, 5030-5036 (2015).
21. J. E. Vince, W. W.-L. Wong, N. Khan, R. Feltham, D. Chau, A. U. Ahmed, C. A. Benetatos, S. K. Chunduru, S. M. Condon, M. McKinlay, R. Brink, M. Leverkus, V. Tergaonkar, P. Schneider, B. A. Callus, F. Koentgen, D. L. Vaux, J. Silke, IAP antagonists target cIAP1 to induce TNFα dependent apoptosis. Cell 131, 682-693 (2007).
22. E. Varfolomeev, J. W. Blankenship, S. M. Wayson, A. V. Fedorova, N. Kayagaki, P. Garg, K. Zobel, J. N. Dynek, L. O. Elliott, H. J. A. Wallweber, J. A. Flygare, W. J. Fairbrother, K. Deshayes, V. M. Dixit, D. Vucic, IAP antagonists induce autoubiquitination of c-IAPs, NF-κB Activation, and TNFα dependent apoptosis. Cell 131, 669-681 (2007).
23. U. Fischer, M. Forster, A. Rinaldi, T. Risch, S. Sungalee, H.-J. Warnatz, B. Bornhauser, M. Gombert, C. Kratsch, A. M. Stütz, M. Sultan, J. Tchinda, C. L. Worth, V. Amstislavskiy, N. Badarinarayan, A. Baruchel, T. Bartram, G. Basso, C. Canpolat, G. Cario, H. Cavé, D. Dakaj, M. Delorenzi, M. P. Dobay, C. Eckert, E. Ellinghaus, S. Eugster, V. Frismantas, S. Ginzel, O. A. Haas, O. Heidenreich, G. Hemmrich-Stanisak, K. Hezaveh, J. I. Höll, S. Hornhardt, P. Husemann, P. Kachroo, C. P. Kratz, G. te Kronnie, B. Marovca, F. Niggli, A. C. McHardy, A. V. Moorman, R. Panzer-Grümayer, B. S. Petersen, B. Raeder, M. Ralser, P. Rosenstiel, D. Schäfer, M. Schrappe, S. Schreiber, M. Schütte, B. Stade, R. Thiele, N. von der Weid, A. Vora, M. Zaliova, L. Zhang, T. Zichner, M. Zimmermann, H. Lehrach, A. Borkhardt, J.-P. Bourquin, A. Franke, J. O. Korbel, M. Stanulla, M.-L. Yaspo, Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat. Genet. 47, 1020-1029 (2015).
24. L. Bonapace, B. C. Bornhauser, M. Schmitz, G. Cario, U. Ziegler, F. K. Niggli, B. W. Schäfer, M. Schrappe, M. Stanulla, J.-P. Bourquin, Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 120, 1310-1323 (2010).
25. J. Boutter, Y. Huang, B. Marovca, A. Vonderheit, M. A. Grotzer, C. Eckert, G. Cario, B. Wollscheid, P. Horvath, B. C. Bornhauser, J.-P. Bourquin, Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget 5, 11501-11512 (2014).
26. M. Schmitz, P. Breithaupt, N. Scheidegger, G. Cario, L. Bonapace, B. Meissner, P. Mirkowska, J. Tchinda, F. K. Niggli, M. Stanulla, M. Schrappe, A. Schrauder, B. C. Bornhauser, J.-P. Bourquin, Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 118, 1854-1864 (2011).
27. E. Clappier, B. Gerby, F. Sigaux, M. Delord, F. Touzri, L. Hernandez, P. Ballerini, A. Baruchel, F. Pflumio, J. Soulier, Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J. Exp. Med. 208, 653-661 (2011).
28. C. A. Benetatos, Y. Mitsuuchi, J. M. Burns, E. M. Neiman, S. M. Condon, G. Yu, M. E. Seipel, G. S. Kapoor, M. G. LaPorte, S. R. Rippin, Y. Deng, M. S. Hendi, P. K. Tirunahari, Y.-H. Lee, T. Haimowitz, M. D. Alexander, M. A. Graham, D. Weng, Y. Shi, M. A. McKinlay, S. K. Chunduru, Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 13, 867-879 (2014).
29. S. L. Petersen, L. Wang, A. Yalcin-Chin, L. Li, M. Peyton, J. Minna, P. Harran, X. Wang, Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445-456 (2007).
30. H. Wu, J. Tschopp, S.-C. Lin, Smac mimetics and TNFα: A dangerous liaison? Cell 131, 655-658 (2007).
31. O. Shalem, N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott, T. S. Mikkelsen, D. Heckl, B. L. Ebert, D. E. Root, J. G. Doench, F. Zhang, Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
32. S. Chen, N. E. Sanjana, K. Zheng, O. Shalem, K. Lee, X. Shi, D. A. Scott, J. Song, J. Q. Pan, R. Weissleder, H. Lee, F. Zhang, P. A. Sharp, Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246-1260 (2015).
33. L. Zheng, N. Bidere, D. Staudt, A. Cubre, J. Orenstein, F. K. Chan, M. Lenardo, Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1. Mol. Cell. Biol. 26, 3505-3513 (2006).
34. J. E. Roderick, N. Hermance, M. Zelic, M. J. Simmons, A. Polykratis, M. Pasparakis, M. A. Kelliher, Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. Proc. Natl. Acad. Sci. 111, 14436-14441 (2014).
35. L. Zender, W. Xue, J. Zuber, C. P. Semighini, A. Krasnitz, B. Ma, P. Zender, S. Kubicka, J. M. Luk, P. Schirmacher, W. R. McCombie, M. Wigler, J. Hicks, G. J. Hannon, S. Powers, S. W. Lowe, An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008).
36. T. Tenev, K. Bianchi, M. Darding, M. Broemer, C. Langlais, F. Wallberg, A. Zachariou, J. Lopez, M. MacFarlane, K. Cain, P. Meier, The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 43, 432-448 (2011).
37. C. Eckert, N. Hagedorn, L. Sramkova, G. Mann, R. Panzer-Grümayer, C. Peters, J.-P. Bourquin, T. Klingebiel, A. Borkhardt, G. Cario, J. Alten, G. Escherich, K. Astrahantseff, K. Seeger, G. Henze, A. von Stackelberg, Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: Prognostic relevance of early and late assessment. Leukemia 29, 1648-1655 (2015).
38. A. Rongvaux, T. Willinger, J. Martinek, T. Strowig, S. V. Gearty, L. L. Teichmann, Y. Saito, F. Marches, S. Halene, A. K. Palucka, M. G. Manz, R. A. Flavell, Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364-372 (2014).
39. J. Zuber, K. McJunkin, C. Fellmann, L. E. Dow, M. J. Taylor, G. J. Hannon, S. W. Lowe, Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat. Biotechnol. 29, 79-83 (2011).
40. R. Rudalska, D. Dauch, T. Longerich, K. McJunkin, T. Wuestefeld, T.-W. Kang, A. Hohmeyer, M. Pesic, J. Leibold, A. von Thun, P. Schirmacher, J. Zuber, K.-H. Weiss, S. Powers, N. P. Malek, M. Eilers, B. Sipos, S. W. Lowe, R. Geffers, S. Laufer, L. Zender, In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med. 20, 1138-1146 (2014).
41. I. L. Ch'en, D. R. Beisner, A. Degterev, C. Lynch, J. Yuan, A. Hoffmann, S. M. Hedrick, Antigenmediated T cell expansion regulated by parallel pathways of death. Proc. Natl. Acad. Sci. U.S.A. 105, 17463-17468 (2008).
42. F. H. Igney, P. H. Krammer, Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277-288 (2002).
43. S. Biton, A. Ashkenazi, NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell 145, 92-103 (2011).
44. Y. Yang, F. Xia, N. Hermance, A. Mabb, S. Simonson, S. Morrissey, P. Gandhi, M. Munson, S. Miyamoto, M. A. Kelliher, A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-κB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol. Cell. Biol. 31, 2774-2786 (2011).
45. S. McComb, E. Cessford, N. A. Alturki, J. Joseph, B. Shutinoski, J. B. Startek, A. M. Gamero, K. L. Mossman, S. Sad, Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. Proc. Natl. Acad. Sci. U.S.A. 111, E3206-E3213 (2014).
46. R. J. Thapa, S. Nogusa, P. Chen, J. L. Maki, A. Lerro, M. Andrake, G. F. Rall, A. Degterev, S. Balachandran, Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc. Natl. Acad. Sci. U.S.A. 110, E3109-E3118 (2013).
47. W. J. Kaiser, H. Sridharan, C. Huang, P. Mandal, J. W. Upton, P. J. Gough, C. A. Sehon, R. W. Marquis, J. Bertin, E. S. Mocarski, Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288, 31268-31279 (2013).
48. S. T. Beug, V. A. Tang, E. C. LaCasse, H. H. Cheung, C. E. Beauregard, J. Brun, J. P. Nuyens, N. Earl, M. St-Jean, J. Holbrook, H. Dastidar, D. J. Mahoney, C. Ilkow, F. Le Boeuf, J. C. Bell, R. G. Korneluk, Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat. Biotechnol. 32, 182-190 (2014).
49. I. Tamm, S. M. Kornblau, H. Segall, S. Krajewski, K. Welsh, S. Kitada, D. A. Scudiero, G. Tudor, Y. H. Qui, A. Monks, M. Andreeff, J. C. Reed, Expression and prognostic significance of IAPfamily genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6, 1796-1803 (2000).
50. J. A. Flygare, W. J. Fairbrother, Small-molecule pan-IAP antagonists: A patent review. Expert Opin. Ther. Pat. 20, 251-267 (2010).
51. J. W. Tyner, W. F. Yang, A. Bankhead III, G. Fan, L. B. Fletcher, J. Bryant, J. M. Glover, B. H. Chang, S. E. Spurgeon, W. H. Fleming, T. Kovacsovics, J. R. Gotlib, S. T. Oh, M. W. Deininger, C. M. Zwaan, M. L. Den Boer, M. M. van den Heuvel-Eibrink, T. O'Hare, B. J. Druker, M. M. Loriaux, Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 73, 285-296 (2013).
52. T. Pemovska, M. Kontro, B. Yadav, H. Edgren, S. Eldfors, A. Szwajda, H. Almusa, M. M. Bespalov, P. Ellonen, E. Elonen, B. T. Gjertsen, R. Karjalainen, E. Kulesskiy, S. Lagström, A. Lehto, M. Lepistö, T. Lundán, M. M. Majumder, J. M. L. Marti, P. Mattila, A. Murumägi, S. Mustjoki, A. Palva, A. Parsons, T. Pirttinen, M. E. Rämet, M. Suvela, L. Turunen, I. Västrik, M. Wolf, J. Knowles, T. Aittokallio, C. A. Heckman, K. Porkka, O. Kallioniemi, K. Wennerberg, Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416-1429 (2013).